Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects

Diabetes

Volumn 53, Issue 3, 2004, Pages 654-662

  Meier, Juris J ^a,e   Nauck, Michael A ^a,b   Kranz, Daniel ^a   Holst, Jens J ^c   Deacon, Carolyn F ^c   Gaeckler, Dirk ^d   Schmidt, Wolfgang E ^a   Gallwitz, Baptist ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b DIABETESZENTRUM BAD LAUTERBERG   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Outpatient Ctr Diabetol/Nephrol   (Germany)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE OXIDASE; INSULIN;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE METABOLISM; HORMONE RELEASE; HUMAN; IMMUNOASSAY; IN VIVO STUDY; INSULIN BLOOD LEVEL; KIDNEY FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATHOGENESIS; PHARMACODYNAMICS; PRIORITY JOURNAL; VENOUS BLOOD;

ANALYSIS OF VARIANCE; CREATININE; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; KIDNEY FAILURE; KINETICS; MALE; MIDDLE AGED; PATIENT SELECTION; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; REFERENCE VALUES;

EID: 1442350411     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.3.654     Document Type: Article

References (50)

1. Creutzfeldt W: The incretin concept today. Diabetologia 16:75-85, 1979
2. Creutzfeldt W, Nauck M: Gut hormones and diabetes mellitus. Diabetes Metab Rev 8:149-177, 1992
3. Meier JJ, Gallwitz B, Nauck MA: Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus. BioDrugs 17:93-102, 2003
4. Drucker DJ: Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122:531-544, 2002
5. Kieffer TJ, McIntosh CH, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596, 1995
6. Deacon CF, Nauck MA, Meier JJ, Hücking K, Holst JJ: Degradation of endogenous and exogenous gastric inhibitory polypeptide (GIP) in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575-3581, 2000
7. Gault VA, Parker JC, Harriott P, Flatt PR, O'Harte FP: Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol 175:525-533, 2002
8. Grandt D, Sieburg B, Sievert J, Schimiczek M, Becker U, Holtmann D, Layer P, Reeve JR, Eysselein VE, Goebell H, Mueller M: Is GLP-1 (9-36) amide an endogenous antagonist at GLP-1 receptors (Abstract)? Digestion 55:302, 1994
9. Knudsen LB, Pridal L: Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318:429-435, 1996
10. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, Porksen N, Schmitz O: Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51:424-429, 2002
11. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, Benquet C, Drucker DJ: Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 52:751-759, 2003
12. a. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson M, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875, 2002
13. Ruiz Grande C, Pintado J, Alarcon C, Castilla C, Valverde I, Lopez Novoa JM: Renal catabolism of human glucagon-like peptides 1 and 2. Can J Physiol Pharmacol 68:1568-1573, 1990
14. Ruiz-Grande C, Alarcón C, Alcántara A, Castila C, López Novoa JM, Villanueva-Peñacarrillo ML, Valverde I: Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res 25:612-616, 1993
15. a. Sirinek KR, O'Dorisio TM, Gaskill HV, Levine BA: Chronic renal failure: effect of hemodialysis on gastrointestinal hormones. Am J Surg 148:732-735, 1984
16. b. Orskov C, Andreasen J, Holst JJ: All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab 74:379-384, 1992
17. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957, 1995
18. Deacon C, Danielsen P, Klarskov L, Olesen M, Holst JJ: Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic effects in anesthetized pigs. Diabetes 50:1588-1597, 2001
19. Deacon CF, Highes TE, Holst JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47:764-769, 1998
20. Ritz E, Orth SR: Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341:1127-1133, 1999
21. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613, 2001
22. Meier JJ, Hücking K, Holst JJ, Deacon C, Schmiegel W, Nauck MA: Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50:2497-2504, 2001
23. 2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 44:1126-1131, 1995
24. Tan GD, Lewis AV, James TJ, Altmann P, Taylor RP, Levy JC: Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance. Diabetes Care 25:2004-2009, 2002
25. Laterza OF, Price CP, Scott MG: Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48:699-707, 2002
26. Finney H, Newman DJ, Gruber W, Merle P, Price CP: Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem 43:1016-1022, 1997
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
28. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
29. Holst JJ: Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 10:229-235, 1999
30. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ: Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol Endocrinol Metab 271:E458-E464, 1996
31. Lojda Z: Studies on dipeptidyl(amino)peptidase IV (glycyl-proline-naphthylamidase). II. Blood vessels. Histochemistry 59:153-166, 1979
32. Mentlein R: Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85:9-24, 1999
33. Peterson DR, Green EA, Oparil S, Hjelle JT: Transport and hydrolysis of glucagon in the proximal nephron. Am J Physiol 251:F460-F467, 1986
34. Deacon CF, Kelstrup M, Trebbien R, Klarskov L, Olesen M, Holst JJ: Differential regional metabolism of glucagon in anesthetized pigs. Am J Physiol Endocrinol Metab 285:E551-E560, 2003
35. Montrose Rafizadeh C, Yang H, Rodgers BD, Beday A, Pritchette LA, Eng J: High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem 272:21201-21206, 1997
36. Wettergren A, Wojdemann M, Holst JJ: The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Peptides 19:877-882, 1998
37. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA: Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88:1772-1779, 2003
38. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ: Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 172:355-362, 2002
39. Vilsboll T, Krarup T, Madsbad S, Holst JJ: Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114:115-121, 2003
40. Hansen L, Deacon CF, Orskov C, Holst JJ: Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dideptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356-5363, 1999
41. Balkan B, Li X: Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 279: R1449-R1454, 2000
42. Ørskov C, Wettergren A, Holst JJ: Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42:658-661, 1993
43. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet 2:1300-1304, 1987
44. Schjoldager BT, Mortensen PE, Christiansen J, Ørskov C, Holst JJ: GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci 34:703-708, 1989
45. Sarson DL, Hayter RC, Bloom SR: The pharmacokinetics of porcine glucose-dependent insulinotropic polypeptide (GIP) in man. Eur J Clin Invest 12:457-461, 1982
46. Nauck M, Schmidt WE, Ebert R, Strietzel J, Cantor P, Hoffmann G, Creutzfeldt W: Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man; interactions with glucose, phenylalanine, and cholezystokinin-8. J Clin Endocrinol Metab 69:654-662, 1989
47. Vilsboll T, Agerso H, Krarup T, Holst JJ: Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220-224, 2003
48. Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB, Holst JJ: In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 85:2884-2888, 2000
49. Ørskov C, Wettergren A, Holst JJ: Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 31:665-670, 1996
50. Wright AD, Lowy C, Fraser TR, Spitz IM, Rubenstein AH, Bersohn I: Serum-growth hormone and glucose intolerance in renal insufficiency. Lancet 2:798-801, 1968